RecruitingNot Applicable

Multi-parametric Imaging in Personalized Radiotherapy

Italy35 participantsStarted 2022-04-19

Plain-language summary

The study consists in the retrospective and prospective collection of imaging data (along with clinical information related to treatment) of skull-base chordoma patients treated with particle therapy, to derive imaging biomarkers which, integrated with advanced mathematical models, will allow predicting treatment outcome on a multi-scale basis.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Patients with histologically confirmed diagnosis of chordoma of the skull base * Particle therapy with curative intent * Karnofsky Performance status greater than or equal to 60 * Patients with macroscopic disease detectable at pre-radiotherapy imaging * Patients undergoing PT with standardized treatment procedures * Patients who have signed the written informed consent for research Exclusion Criteria: * Metastatic disease * Palliative treatment * Other malignancies with disease-free interval \< 5 years (excepting pre- cancerous lesions) * Pregnancy * Simultaneous CHT or Immunotherapy * Extensive metal instrumentation/implants * Patients with autoimmune diseases (ADs) -including collagen-vascular (CVD) and inflammatory bowel (IBD)

What they're measuring

collect data from MRI acquisition

Timeframe: 1 year from the treatment provided in routine clinical setting

Trial details

NCT IDNCT05888064

SponsorCNAO National Center of Oncological Hadrontherapy

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2025-08-18

Contact for this trial

Alberto Iannalfi, MD

0382078501 alberto.iannalfi@cnao.it

View on ClinicalTrials.gov More Skull Base Chordoma trials